Cancer immunotherapy: Strategies for personalization and combinatorial approaches

Molecular Oncology

Volumn 9, Issue 10, 2015, Pages 2043-2053

  Sathyanarayanan, Vishwanath ^a   Neelapu, Sattva S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Immune checkpoint; Immunotherapy; Personalized; T cells

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CANCER VACCINE; CYANOCOBALAMIN; IMMUNE CHECKPOINT ANTAGONIST; INTRINSIC FACTOR; MONOCLONAL ANTIBODY; ONCOLYTIC VIRUS; RADIOISOTOPE; STIMULATORY AGONIST; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL THERAPY; HUMAN; IMMUNOCOMPETENT CELL; MULTIMODALITY CANCER THERAPY; ONCOLYTIC VIROTHERAPY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; IMMUNOTHERAPY; NEOPLASMS;

HUMANS; IMMUNOTHERAPY; NEOPLASMS; PRECISION MEDICINE;

EID: 84952638598     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.10.009     Document Type: Review

References (99)

1. Angell H., Galon J. From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer. Curr. Opin. Immunol. 2013, 25:261-267.
2. Ansell S.M., Lesokhin A.M., Borrello I., Halwani A., Scott E.C., Gutierrez M., Schuster S.J., Millenson M.M., Cattry D., Freeman G.J., Rodig S.J., Chapuy B., Ligon A.H., Zhu L., Grosso J.F., Kim S.Y., Timmerman J.M., Shipp M.A., Armand P. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New Engl. J. Med. 2015, 372:311-319.
3. Bartlett D.L., Liu Z., Sathaiah M., Ravindranathan R., Guo Z., He Y., Guo Z.S. Oncolytic viruses as therapeutic cancer vaccines. Mol. Cancer 2013, 12:103.
4. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
5. Blackburn S.D., Shin H., Haining W.N., Zou T., Workman C.J., Polley A., Betts M.R., Freeman G.J., Vignali D.A., Wherry E.J. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 2009, 10:29-37.
6. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., Pitot H.C., Hamid O., Bhatia S., Martins R., Eaton K., Chen S., Salay T.M., Alaparthy S., Grosso J.F., Korman A.J., Parker S.M., Agrawal S., Goldberg S.M., Pardoll D.M., Gupta A., Wigginton J.M. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New Engl. J. Med. 2012, 366:2455-2465.
7. Brody J.D., Ai W.Z., Czerwinski D.K., Torchia J.A., Levy M., Advani R.H., Kim Y.H., Hoppe R.T., Knox S.J., Shin L.K., Wapnir I., Tibshirani R.J., Levy R. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J. Clin. Oncol. 2010, 28:4324-4332.
8. Bulliard Y., Jolicoeur R., Windman M., Rue S.M., Ettenberg S., Knee D.A., Wilson N.S., DranoffG., Brogdon J.L. Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J. Exp. Med. 2013, 210:1685-1693.
9. Carreno B.M., Magrini V., Becker-Hapak M., Kaabinejadian S., Hundal J., Petti A.A., Ly A., Lie W.R., Hildebrand W.H., Mardis E.R., Linette G.P. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015, 348:803-808.
10. Challa-Malladi M., Lieu Y.K., Califano O., Holmes A.B., Bhagat G., Murty V.V., Dominguez-Sola D., Pasqualucci L., Dalla-Favera R. Combined genetic inactivation of beta2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 2011, 20:728-740.
11. Chen D.S., Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013, 39:1-10.
12. Cheson B.D., Leonard J.P. Monoclonal antibody therapy for b-cell non-Hodgkin's lymphoma. New Engl. J. Med. 2008, 359:613-626.
13. Cohen C.J., Gartner J.J., Horovitz-Fried M., Shamalov K., Trebska-McGowan K., Bliskovsky V.V., Parkhurst M.R., Ankri C., Prickett T.D., Crystal J.S., Li Y.F., El-Gamil M., Rosenberg S.A., Robbins P.F. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J. Clin. Invest. 2015 Oct 1, 125(10):3981-3991.
14. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M.L., Knutson K.L., Chen L., Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
15. Curran M.A., Montalvo W., Yagita H., Allison J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:4275-4280.
16. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., Mackey E.W., Miller J.D., Leslie A.J., DePierres C., Mncube Z., Duraiswamy J., Zhu B., Eichbaum Q., Altfeld M., Wherry E.J., Coovadia H.M., Goulder P.J., Klenerman P., Ahmed R., Freeman G.J., Walker B.D. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
17. Dengel L.T., Norrod A.G., Gregory B.L., Clancy-Thompson E., Burdick M.D., Strieter R.M., SlingluffC.L., Mullins D.W. Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma. J. Immunother. 2010, 33:965-974.
18. Ehrlich P. Collected Studies on Immunity 1906, J. Wiley & Sons, New York.
19. Farinha P., Masoudi H., Skinnider B.F., Shumansky K., Spinelli J.J., Gill K., Klasa R., Voss N., Connors J.M., Gascoyne R.D. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005, 106:2169-2174.
20. Geukes Foppen M.H., Donia M., Svane I.M., Haanen J.B.A.G. Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. Mol. Oncol. 2015, 9:1918-1935.
21. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268.
22. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., Zinzindohoue F., Bruneval P., Cugnenc P.H., Trajanoski Z., Fridman W.H., Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
23. Garon E.B., Rizvi N.A., Hui R., Leighl N., Balmanoukian A.S., Eder J.P., Patnaik A., Aggarwal C., Gubens M., Horn L., Carcereny E., Ahn M.J., Felip E., Lee J.S., Hellmann M.D., Hamid O., Goldman J.W., Soria J.C., Dolled-Filhart M., Rutledge R.Z., Zhang J., Lunceford J.K., Rangwala R., Lubiniecki G.M., Roach C., Emancipator K., Gandhi L., Investigators K. Pembrolizumab for the treatment of non-small-cell lung cancer. New Engl. J. Med. 2015, 372:2018-2028.
24. Greaves P., Gribben J.G. The role of B7 family molecules in hematologic malignancy. Blood 2013, 121:734-744.
25. Green M.R., Kihira S., Liu C.L., Nair R.V., Salari R., Gentles A.J., Irish J., Stehr H., Vicente-Duenas C., Romero-Camarero I., Sanchez-Garcia I., Plevritis S.K., Arber D.A., Batzoglou S., Levy R., Alizadeh A.A. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:E1116-E1125.
26. Gros A., Robbins P.F., Yao X., Li Y.F., Turcotte S., Tran E., Wunderlich J.R., Mixon A., Farid S., Dudley M.E., Hanada K., Almeida J.R., Darko S., Douek D.C., Yang J.C., Rosenberg S.A. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 2014, 124:2246-2259.
27. Gubin M.M., Zhang X., Schuster H., Caron E., Ward J.P., Noguchi T., Ivanova Y., Hundal J., Arthur C.D., Krebber W.J., Mulder G.E., Toebes M., Vesely M.D., Lam S.S., Korman A.J., Allison J.P., Freeman G.J., Sharpe A.H., Pearce E.L., Schumacher T.N., Aebersold R., Rammensee H.G., Melief C.J., Mardis E.R., Gillanders W.E., Artyomov M.N., Schreiber R.D. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515:577-581.
28. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., Wolchok J.D., Hersey P., Joseph R.W., Weber J.S., Dronca R., Gangadhar T.C., Patnaik A., Zarour H., Joshua A.M., Gergich K., Elassaiss-Schaap J., Algazi A., Mateus C., Boasberg P., Tumeh P.C., Chmielowski B., Ebbinghaus S.W., Li X.N., Kang S.P., Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. New Engl. J. Med. 2013, 369:134-144.
29. Harlin H., Meng Y., Peterson A.C., Zha Y., Tretiakova M., SlingluffC., McKee M., Gajewski T.F. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009, 69:3077-3085.
30. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den Eertwegh A.J., Lutzky J., Lorigan P., Vaubel J.M., Linette G.P., Hogg D., Ottensmeier C.H., Lebbe C., Peschel C., Quirt I., Clark J.I., Wolchok J.D., Weber J.S., Tian J., Yellin M.J., Nichol G.M., Hoos A., Urba W.J. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl. J. Med. 2010, 363:711-723.
31. Houot R., Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 2009, 113:3546-3552.
32. Houot R., Goldstein M.J., Kohrt H.E., Myklebust J.H., Alizadeh A.A., Lin J.T., Irish J.M., Torchia J.A., Kolstad A., Chen L., Levy R. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 2009, 114:3431-3438.
33. Johnson D.B., Puzanov I., Kelley M.C. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy 2015, 7:611-619.
34. June C.H., Riddell S.R., Schumacher T.N. Adoptive cellular therapy: a race to the finish line. Sci. Transl. Med. 2015, 7. 280ps287.
35. Kalos M., Levine B.L., Porter D.L., Katz S., Grupp S.A., Bagg A., June C.H. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 2011, 3. 95ra73.
36. KantoffP.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Redfern C.H., Ferrari A.C., Dreicer R., Sims R.B., Xu Y., Frohlich M.W., Schellhammer P.F. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl. J. Med. 2010, 363:411-422.
37. Karpanen T., Olweus J. T-cell receptor gene therapy - ready to go viral?. Mol. Oncol. 2015, 9:2019-2042.
38. Kim Y.H., Gratzinger D., Harrison C., Brody J.D., Czerwinski D.K., Ai W.Z., Morales A., Abdulla F., Xing L., Navi D., Tibshirani R.J., Advani R.H., Lingala B., Shah S., Hoppe R.T., Levy R. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood 2012, 119:355-363.
39. Kochenderfer J.N., Wilson W.H., Janik J.E., Dudley M.E., Stetler-Stevenson M., Feldman S.A., Maric I., Raffeld M., Nathan D.A., Lanier B.J., Morgan R.A., Rosenberg S.A. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116:4099-4102.
40. Kochenderfer J.N., Dudley M.E., Feldman S.A., Wilson W.H., Spaner D.E., Maric I., Stetler-Stevenson M., Phan G.Q., Hughes M.S., Sherry R.M., Yang J.C., Kammula U.S., Devillier L., Carpenter R., Nathan D.A., Morgan R.A., Laurencot C., Rosenberg S.A. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-2720.
41. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
42. Kohrt H.E., Houot R., Goldstein M.J., Weiskopf K., Alizadeh A.A., Brody J., Muller A., Pachynski R., Czerwinski D., Coutre S., Chao M.P., Chen L., Tedder T.F., Levy R. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011, 117:2423-2432.
43. Kohrt H.E., Thielens A., Marabelle A., Sagiv-BarfiI., Sola C., Chanuc F., Fuseri N., Bonnafous C., Czerwinski D., Rajapaksa A., Waller E., Ugolini S., Vivier E., Romagne F., Levy R., Blery M., Andre P. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 2014, 123:678-686.
44. Kolstad A., Kumari S., Walczak M., Madsbu U., Hagtvedt T., Bogsrud T.V., Kvalheim G., Holte H., Aurlien E., Delabie J., Tierens A., Olweus J. Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. Blood 2015, 125:82-89.
45. Kraeber-Bodere F., Bodet-Milin C., Rousseau C., Eugene T., Pallardy A., Frampas E., Carlier T., Ferrer L., Gaschet J., Davodeau F., Gestin J.F., Faivre-Chauvet A., Barbet J., Cherel M. Radioimmunoconjugates for the treatment of cancer. Semin. Oncol. 2014, 41:613-622.
46. Kroemer G., Galluzzi L., Kepp O., Zitvogel L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 2013, 31:51-72.
47. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-1736.
48. Lesokhin A.M., A S., Armand P., et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood 2014, 124(21). (ASH Annual Meeting Abstracts), Abstract 291.
49. Linnemann C., van Buuren M.M., Bies L., Verdegaal E.M., Schotte R., Calis J.J., Behjati S., Velds A., Hilkmann H., Atmioui D.E., Visser M., Stratton M.R., Haanen J.B., Spits H., van der Burg S.H., Schumacher T.N. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med. 2015, 21:81-85.
50. Mahmoud S.M., Paish E.C., Powe D.G., Macmillan R.D., Grainge M.J., Lee A.H., Ellis I.O., Green A.R. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J. Clin. Oncol. 2011, 29:1949-1955.
51. Marabelle A., Kohrt H., Sagiv-BarfiI., Ajami B., Axtell R.C., Zhou G., Rajapaksa R., Green M.R., Torchia J., Brody J., Luong R., Rosenblum M.D., Steinman L., Levitsky H.I., Tse V., Levy R. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J. Clin. Invest. 2013, 123:2447-2463.
52. Marvel D., Gabrilovich D.I. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J. Clin. Invest. 2015, 125:3356-3364.
53. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., Heyman M.R., Bence-Bruckler I., White C.A., Cabanillas F., Jain V., Ho A.D., Lister J., Wey K., Shen D., Dallaire B.K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 1998, 16:2825-2833.
54. Mellman I., Coukos G., DranoffG. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
55. Michaud M., Martins I., Sukkurwala A.Q., Adjemian S., Ma Y., Pellegatti P., Shen S., Kepp O., Scoazec M., Mignot G., Rello-Varona S., Tailler M., Menger L., Vacchelli E., Galluzzi L., Ghiringhelli F., di Virgilio F., Zitvogel L., Kroemer G. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011, 334:1573-1577.
56. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., Royal R.E., Topalian S.L., Kammula U.S., Restifo N.P., Zheng Z., Nahvi A., de Vries C.R., Rogers-Freezer L.J., Mavroukakis S.A., Rosenberg S.A. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
57. Newman A.M., Liu C.L., Green M.R., Gentles A.J., Feng W., Xu Y., Hoang C.D., Diehn M., Alizadeh A.A. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 2015, 12:453-457.
58. Olsen E., Duvic M., Frankel A., Kim Y., Martin A., Vonderheid E., Jegasothy B., Wood G., Gordon M., Heald P., OseroffA., Pinter-Brown L., Bowen G., Kuzel T., Fivenson D., Foss F., Glode M., Molina A., Knobler E., Stewart S., Cooper K., Stevens S., Craig F., Reuben J., Bacha P., Nichols J. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 2001, 19:376-388.
59. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12:252-264.
60. Peggs K.S., Quezada S.A., Chambers C.A., Korman A.J., Allison J.P. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 2009, 206:1717-1725.
61. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New Engl. J. Med. 2011, 365:725-733.
62. Postow M.A., Callahan M.K., Barker C.A., Yamada Y., Yuan J., Kitano S., Mu Z., Rasalan T., Adamow M., Ritter E., Sedrak C., Jungbluth A.A., Chua R., Yang A.S., Roman R.A., Rosner S., Benson B., Allison J.P., Lesokhin A.M., Gnjatic S., Wolchok J.D. Immunologic correlates of the abscopal effect in a patient with melanoma. New Engl. J. Med. 2012, 366:925-931.
63. Przepiorka D., Ko C.W., Deisseroth A., Yancey C.L., Candau-Chacon R., Chiu H.J., Gehrke B.J., Gomez-Broughton C., Kane R.C., Kirshner S., Mehrotra N., Ricks T.K., Schmiel D., Song P., Zhao P., Zhou Q., Farrell A.T., Pazdur R. FDA approval: blinatumomab. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2015, 21:4035-4039.
64. Quezada S.A., Peggs K.S., Curran M.A., Allison J.P. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 2006, 116:1935-1945.
65. Rawal S., Chu F., Zhang M., Park H.J., Nattamai D., Kannan S., Sharma R., Delgado D., Chou T., Lin H.Y., Baladandayuthapani V., Luong A., Vega F., Fowler N., Dong C., Davis R.E., Neelapu S.S. Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. J. Immunol. 2013, 190:6681-6693.
66. Rizvi N.A., Hellmann M.D., Snyder A., Kvistborg P., Makarov V., Havel J.J., Lee W., Yuan J., Wong P., Ho T.S., Miller M.L., Rekhtman N., Moreira A.L., Ibrahim F., Bruggeman C., Gasmi B., Zappasodi R., Maeda Y., Sander C., Garon E.B., Merghoub T., Wolchok J.D., Schumacher T.N., Chan T.A. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015, 348:124-128.
67. Robbins P.F., Morgan R.A., Feldman S.A., Yang J.C., Sherry R.M., Dudley M.E., Wunderlich J.R., Nahvi A.V., Helman L.J., Mackall C.L., Kammula U.S., Hughes M.S., Restifo N.P., Raffeld M., Lee C.C., Levy C.L., Li Y.F., El-Gamil M., Schwarz S.L., Laurencot C., Rosenberg S.A. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 2011, 29:917-924.
68. Robbins P.F., Lu Y.C., El-Gamil M., Li Y.F., Gross C., Gartner J., Lin J.C., Teer J.K., Cliften P., Tycksen E., Samuels Y., Rosenberg S.A. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 2013, 19:747-752.
69. Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., Citrin D.E., Restifo N.P., Robbins P.F., Wunderlich J.R., Morton K.E., Laurencot C.M., Steinberg S.M., White D.E., Dudley M.E. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2011, 17:4550-4557.
70. Rosenberg S.A. Raising the bar: the curative potential of human cancer immunotherapy. Sci. Transl. Med. 2012, 4. 127ps128.
71. Sanchez-Espiridion B., Martin-Moreno A.M., Montalban C., Medeiros L.J., Vega F., Younes A., Piris M.A., Garcia J.F. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica 2012, 97:1080-1084.
72. Schuster S.J., Neelapu S.S., Gause B.L., Janik J.E., Muggia F.M., Gockerman J.P., Winter J.N., Flowers C.R., Nikcevich D.A., Sotomayor E.M., McGaughey D.S., Jaffe E.S., Chong E.A., Reynolds C.W., Berry D.A., Santos C.F., Popa M.A., McCord A.M., Kwak L.W. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 2011, 29:2787-2794.
73. Schwartzentruber D.J., Lawson D.H., Richards J.M., Conry R.M., Miller D.M., Treisman J., Gailani F., Riley L., Conlon K., Pockaj B., Kendra K.L., White R.L., Gonzalez R., Kuzel T.M., Curti B., Leming P.D., Whitman E.D., Balkissoon J., Reintgen D.S., Kaufman H., Marincola F.M., Merino M.J., Rosenberg S.A., Choyke P., Vena D., Hwu P. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. New Engl. J. Med. 2011, 364:2119-2127.
74. Simpson T.R., Li F., Montalvo-Ortiz W., Sepulveda M.A., BergerhoffK., Arce F., Roddie C., Henry J.Y., Yagita H., Wolchok J.D., Peggs K.S., Ravetch J.V., Allison J.P., Quezada S.A. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 2013, 210:1695-1710.
75. Sistigu A., Yamazaki T., Vacchelli E., Chaba K., Enot D.P., Adam J., Vitale I., Goubar A., Baracco E.E., Remedios C., Fend L., Hannani D., Aymeric L., Ma Y., Niso-Santano M., Kepp O., Schultze J.L., Tuting T., Belardelli F., Bracci L., La Sorsa V., Ziccheddu G., Sestili P., Urbani F., Delorenzi M., Lacroix-Triki M., Quidville V., Conforti R., Spano J.P., Pusztai L., Poirier-Colame V., Delaloge S., Penault-Llorca F., Ladoire S., Arnould L., Cyrta J., Dessoliers M.C., Eggermont A., Bianchi M.E., Pittet M., Engblom C., Pfirschke C., Preville X., Uze G., Schreiber R.D., Chow M.T., Smyth M.J., Proietti E., Andre F., Kroemer G., Zitvogel L. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 2014, 20:1301-1309.
76. Śledzińska A., Menger L., BergerhoffK., Peggs K.S., Quezada S.A. Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Mol. Oncol. 2015, 9:1936-1965.
77. Snyder A., Makarov V., Merghoub T., Yuan J., Zaretsky J.M., Desrichard A., Walsh L.A., Postow M.A., Wong P., Ho T.S., Hollmann T.J., Bruggeman C., Kannan K., Li Y., Elipenahli C., Liu C., Harbison C.T., Wang L., Ribas A., Wolchok J.D., Chan T.A. Genetic basis for clinical response to CTLA-4 blockade in melanoma. New Engl. J. Med. 2014, 371:2189-2199.
78. Taube J.M., Anders R.A., Young G.D., Xu H., Sharma R., McMiller T.L., Chen S., Klein A.P., Pardoll D.M., Topalian S.L., Chen L. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 2012, 4. 127ra137.
79. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., Leming P.D., Spigel D.R., Antonia S.J., Horn L., Drake C.G., Pardoll D.M., Chen L., Sharfman W.H., Anders R.A., Taube J.M., McMiller T.L., Xu H., Korman A.J., Jure-Kunkel M., Agrawal S., McDonald D., Kollia G.D., Gupta A., Wigginton J.M., Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl. J. Med. 2012, 366:2443-2454.
80. Tosolini M., Kirilovsky A., Mlecnik B., Fredriksen T., Mauger S., Bindea G., Berger A., Bruneval P., Fridman W.H., Pages F., Galon J. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011, 71:1263-1271.
81. Tran E., Turcotte S., Gros A., Robbins P.F., Lu Y.C., Dudley M.E., Wunderlich J.R., Somerville R.P., Hogan K., Hinrichs C.S., Parkhurst M.R., Yang J.C., Rosenberg S.A. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014, 344:641-645.
82. Tumeh P.C., Harview C.L., Yearley J.H., Shintaku I.P., Taylor E.J., Robert L., Chmielowski B., Spasic M., Henry G., Ciobanu V., West A.N., Carmona M., Kivork C., Seja E., Cherry G., Gutierrez A.J., Grogan T.R., Mateus C., Tomasic G., Glaspy J.A., Emerson R.O., Robins H., Pierce R.H., ElashoffD.A., Robert C., Ribas A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515:568-571.
83. Van Cutsem E., Kohne C.H., Hitre E., Zaluski J., Chang Chien C.R., Makhson A., D'Haens G., Pinter T., Lim R., Bodoky G., Roh J.K., Folprecht G., RuffP., Stroh C., Tejpar S., Schlichting M., Nippgen J., Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. New Engl. J. Med. 2009, 360:1408-1417.
84. van Rooij N., van Buuren M.M., Philips D., Velds A., Toebes M., Heemskerk B., van Dijk L.J., Behjati S., Hilkmann H., El Atmioui D., Nieuwland M., Stratton M.R., Kerkhoven R.M., Kesmir C., Haanen J.B., Kvistborg P., Schumacher T.N. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 2013, 31:e439-e442.
85. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20:719-726.
86. Voo K.S., Bover L., Harline M.L., Vien L.T., Facchinetti V., Arima K., Kwak L.W., Liu Y.J. Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. J. Immunol. 2013, 191:3641-3650.
87. Weiner L.M., Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10:317-327.
88. Weiner G.J. Building better monoclonal antibody-based therapeutics. Nat. Rev. Cancer 2015, 15:361-370.
89. Westin J.R., Chu F., Zhang M., Fayad L.E., Kwak L.W., Fowler N., Romaguera J., Hagemeister F., Fanale M., Samaniego F., Feng L., Baladandayuthapani V., Wang Z., Ma W., Gao Y., Wallace M., Vence L.M., Radvanyi L., Muzzafar T., Rotem-Yehudar R., Davis R.E., Neelapu S.S. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014, 15:69-77.
90. Wherry E.J. T cell exhaustion. Nat. Immunol. 2011, 12:492-499.
91. Whilding L.M., Maher J. CAR T-cell immunotherapy: the path from the by-road to the freeway?. Mol. Oncol. 2015, 9:1994-2018.
92. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., Segal N.H., Ariyan C.E., Gordon R.A., Reed K., Burke M.M., Caldwell A., Kronenberg S.A., Agunwamba B.U., Zhang X., Lowy I., Inzunza H.D., Feely W., Horak C.E., Hong Q., Korman A.J., Wigginton J.M., Gupta A., Sznol M. Nivolumab plus ipilimumab in advanced melanoma. New Engl. J. Med. 2013, 369:122-133.
93. Yang Z.Z., Novak A.J., Stenson M.J., Witzig T.E., Ansell S.M. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006, 107:3639-3646.
94. Yang Z.Z., Novak A.J., Ziesmer S.C., Witzig T.E., Ansell S.M. Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 2006, 66:10145-10152.
95. Younes A., Bartlett N.L., Leonard J.P., Kennedy D.A., Lynch C.M., Sievers E.L., Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. New Engl. J. Med. 2010, 363:1812-1821.
96. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., Rubin S.C., Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New Engl. J. Med. 2003, 348:203-213.
97. Zolot R.S., Basu S., Million R.P. Antibody-drug conjugates. Nat. Rev. Drug Discov. 2013, 12:259-260.
98. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 2005, 5:263-274.
99. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 2006, 6:295-307.